NASDAQ : ACLX
Arcellx, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 115.07 USD (Apr 27, 2026, 4:00 PM EDT) · Market cap 6.75B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.75B |
| Enterprise Value | 6.28B |
Dates
| Measure | Value |
|---|
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 58.67M |
| Shares Outstanding | 58.67M |
| Shares Change (YoY) | +5.11% |
| Shares Change (QoQ) | +2.30% |
| Owned by Insiders (%) | 1.41% |
| Owned by Institutions (%) | 68.95% |
| Float | 42.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 302.95 |
| Forward PS | 103.11 |
| PB Ratio | 16.57 |
| P/TBV Ratio | 16.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 281.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.44 |
| Quick Ratio | 4.32 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -53.42% |
| Return on Assets (ROA) | -24.05% |
| Return on Invested Capital (ROIC) | -32.85% |
| Return on Capital Employed (ROCE) | -50.64% |
| Weighted Average Cost of Capital (WACC) | 5.57% |
| Revenue Per Employee | $106,632 |
| Profits Per Employee | -$1.10M |
| Employee Count | 209 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 69,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +80.62% |
| 50-Day Moving Average | 109.88 |
| 200-Day Moving Average | 83.49 |
| Relative Strength Index (RSI) | 79.85 |
| Average Volume (20 Days) | 1,561,082 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.80M |
| Short Previous Month | 2.27M |
| Short % of Shares Out | 3.07% |
| Short % of Float | 4.25% |
| Short Ratio (days to cover) | 1.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 22.29M |
| Gross Profit | -135.33M |
| Operating Income | -253.08M |
| Pretax Income | -228.87M |
| Net Income | -228.93M |
| EBITDA | -246.41M |
| EBIT | -253.08M |
| Loss Per Share | -$4.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 450.33M |
| Total Debt | 51.92M |
| Net Cash | 468.13M |
| Net Cash Per Share | $7.98 |
| Equity (Book Value) | 402.35M |
| Book Value Per Share | 6.95 |
| Working Capital | 357.98M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -210.26M |
| Capital Expenditures | -2.33M |
| Depreciation & Amortization | 6.68M |
| Net Borrowing | -230,000 |
| Free Cash Flow | -212.59M |
| FCF Per Share | -$3.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,135.61% |
| Pretax Margin | -1,026.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.11% |
| Shareholder Yield | -5.11% |
| Earnings Yield | -3.39% |
| FCF Yield | -3.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $118.17 |
| Price Target Difference | 2.69% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 9.33 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |